Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDeferred TaxesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Sanofi (SNY) over the last 8 years, with Q4 2025 value amounting to $7.3 billion.

  • Sanofi's Free Cash Flow rose 9681.36% to $7.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $19.7 billion, marking a year-over-year increase of 4761.04%. This contributed to the annual value of $8.2 billion for FY2025, which is 2793.52% up from last year.
  • Per Sanofi's latest filing, its Free Cash Flow stood at $7.3 billion for Q4 2025, which was up 9681.36% from $8.5 billion recorded in Q3 2025.
  • Sanofi's 5-year Free Cash Flow high stood at $11.4 billion for Q4 2021, and its period low was -$495.4 million during Q2 2024.
  • Over the past 5 years, Sanofi's median Free Cash Flow value was $3.1 billion (recorded in 2022), while the average stood at $4.4 billion.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 507587.54% in 2021, then tumbled by 15568.12% in 2024.
  • Sanofi's Free Cash Flow (Quarter) stood at $11.4 billion in 2021, then fell by 2.05% to $11.2 billion in 2022, then tumbled by 56.56% to $4.9 billion in 2023, then dropped by 23.31% to $3.7 billion in 2024, then surged by 96.81% to $7.3 billion in 2025.
  • Its Free Cash Flow was $7.3 billion in Q4 2025, compared to $8.5 billion in Q3 2025 and $1.6 billion in Q2 2025.